Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
Current NICE guidelines for type 2 diabetes (T2D) recommend identifying the most appropriate glucose-lowering therapy for a given individual. This decision depends not only on the initial glycaemic response, but also the durability of its glucose lowering effect over time. We investigated the latter...
| Κύριοι συγγραφείς: | , , , , , |
|---|---|
| Μορφή: | Conference item |
| Έκδοση: |
Springer
2017
|